Skip to main content

Table 1 Physical data and antimycobacterial activities of compound (6a-i), (7a-i), (8a-i), and (9a-i) against MTB H37Rv

From: Synthesis and biological evaluation of some 4-aminoquinoline derivatives as potential antitubercular agents

View full size image
Comp.RMol. formulaMelting point (°C)aMIC (μM)bDrug scorec
6a4-CH3C26H22ClN5S196–19812.50.69
6b4-OCH3C26H22ClN5OS190–19212.51.02
6c3,4-OCH3C27H24ClN5O2S148–15025.01.09
6d3,4,5-OCH3C28H26ClN5O3S138–14012.50.98
6e4-ClC25H19Cl2N5S142–14312.50.78
6f4-FC25H19ClFN5S178–18050.00.75
6 g4-BrC25H19BrClN5S186–18850.00.58
6 h4-NO2C25H19ClN6O2S216–21850.00.24
6i4-OHC25H20ClN5OS230–23250.00.88
7a4-CH3C26H22ClN5O148–1506.250.87
7b4-OCH3C26H22ClN5O2238–24025.01.12
7c3,4-OCH3C27H24ClN5O3214–2161.561.18
7d3,4,5-OCH3C28H26ClN5O4238–24012.51.07
7e4-ClC25H19Cl2N5O174–18612.50.96
7f4-FC25H19ClFN5O230–23225.00.94
7 g4-BrC25H19BrClN5O244–2461.560.76
7 h4-NO2C25H19ClN6O3196–19812.50.35
7i4-OHC25H20ClN5O2240–2426.251.07
8a4-CH3C26H22ClN5S238–24012.50.55
8b4-OCH3C26H22ClN5OS210–21225.00.86
8c3,4-OCH3C27H24ClN5O2S120–12225.00.94
8d3,4,5-OCH3C28H26ClN5O3S240–24225.00.85
8e4-ClC25H19Cl2N5S212–21425.00.62
8f4-FC25H19ClFN5S234–23650.00.60
8 g4-BrC25H19BrClN5S238–24025.00.43
8 h4-NO2C25H19ClN6O2S218–22025.00.13
8i4-OHC25H20ClN5OS250–25250.00.71
9a4-CH3C26H22ClN5O192–1946.250.73
9b4-OCH3C26H22ClN5O2188–19012.50.96
9c3,4-OCH3C27H24ClN5O3254–25612.51.03
9d3,4,5-OCH3C28H26ClN5O4258–26025.00.94
9e4-ClC25H19Cl2N5O226–22825.00.80
9f4-FC25H19ClFN5O198–20025.00.78
9 g4-BrC25H19BrClN5O306–30825.00.61
9 h4-NO2C25H19ClN6O3246–24825.00.25
9i4-OHC25H20ClN5O2234–23625.00.90
INHdC6H7N3O1.560.53
PyraeC5H5N3O50.0− 0.15
CiprofC17H18FN3O312.50.93
  1. aThe melting points were determined in open capillary tubes and are uncorrected
  2. bMinimum inhibitory concentration against Mycobacterium tuberculosis H37Rv
  3. cCalculated using molsoft (http://molsoft.com/mprop/)
  4. dIsoniazid
  5. ePyrazinamide
  6. fCiprofloxacin